Nouveau Life Pharmaceuticals Stock Fundamentals
Nouveau Life Pharmaceuticals fundamentals help investors to digest information that contributes to Nouveau Life's financial success or failures. It also enables traders to predict the movement of Nouveau Pink Sheet. The fundamental analysis module provides a way to measure Nouveau Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nouveau Life pink sheet.
Nouveau |
Nouveau Life Pharmaceuticals Company Return On Equity Analysis
Nouveau Life's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nouveau Life Return On Equity | -2.2 |
Most of Nouveau Life's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nouveau Life Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Nouveau Life Pharmaceuticals has a Return On Equity of -2.1952. This is 251.39% lower than that of the Financial Services sector and significantly lower than that of the Shell Companies industry. The return on equity for all United States stocks is notably higher than that of the company.
Nouveau Life Pharmac Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nouveau Life's current stock value. Our valuation model uses many indicators to compare Nouveau Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nouveau Life competition to find correlations between indicators driving Nouveau Life's intrinsic value. More Info.Nouveau Life Pharmaceuticals is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nouveau Life's earnings, one of the primary drivers of an investment's value.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
Nouveau Fundamentals
| Return On Equity | -2.2 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 722.68 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 22.72 X | |||
| EBITDA | (163.87 K) | |||
| Net Income | (357.25 K) | |||
| Cash And Equivalents | 1.1 K | |||
| Cash Flow From Operations | (22.91 K) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | -4.22 | |||
| Market Capitalization | 484.8 K | |||
| Total Asset | 1.33 M | |||
| Retained Earnings | (236 K) | |||
| Working Capital | (145 K) | |||
| Current Asset | 1 K | |||
| Current Liabilities | 146 K | |||
| Net Asset | 1.33 M |
About Nouveau Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nouveau Life Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nouveau Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nouveau Life Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Nouveau Life Pharmaceuticals, Inc., a development stage company, engages in the development of nutraceuticals products. Nouveau Life Pharmaceuticals, Inc. operates as a subsidiary of EMG Marketing Solutions, Inc. Nouveau Life is traded on OTC Exchange in the United States.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nouveau Pink Sheet Analysis
When running Nouveau Life's price analysis, check to measure Nouveau Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nouveau Life is operating at the current time. Most of Nouveau Life's value examination focuses on studying past and present price action to predict the probability of Nouveau Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nouveau Life's price. Additionally, you may evaluate how the addition of Nouveau Life to your portfolios can decrease your overall portfolio volatility.